p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy

Jack D Chan; Paul A Beavis; Phillip K Darcy

doi:10.1016/j.ccell.2020.05.012

p38 Kinase: A Key Target for Driving Potent T Cells for Adoptive Immunotherapy

Cancer Cell. 2020 Jun 8;37(6):756-758. doi: 10.1016/j.ccell.2020.05.012.

Authors

Jack D Chan¹, Paul A Beavis², Phillip K Darcy³

Affiliations

¹ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia.
² Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia. Electronic address: Paul.Beavis@petermac.org.
³ Cancer Immunology Program, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, VIC 3010, Australia; Department of Pathology, University of Melbourne, Parkville, VIC, Australia; Department of Immunology, Monash University, Clayton, VIC, Australia. Electronic address: phil.darcy@petermac.org.

PMID: 32516586
DOI: 10.1016/j.ccell.2020.05.012

Abstract

In this issue of Cancer Cell, Gurusamy et al. use a CRISPR-Cas9 screening approach to demonstrate that deletion of p38 increases multiple phenotypic qualities of effective anti-tumor T cells. Preconditioning T cells with a p38 inhibitor enhances anti-tumor efficacy of adoptive immunotherapy.

Publication types

Research Support, Non-U.S. Gov't
Comment

MeSH terms

CRISPR-Cas Systems
Gene Editing
Immunotherapy, Adoptive*
Phenotype
T-Lymphocytes*